A phase 3 trial of SC0062 in China
Latest Information Update: 01 Oct 2024
At a glance
- Drugs SC-0062 (Primary)
- Indications Diabetic neuropathies; IgA nephropathy
- Focus Adverse reactions; Registrational; Therapeutic Use
- 01 Oct 2024 New trial record
Latest Information Update: 01 Oct 2024